Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.
Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders
Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.
